Explore our high-purity commercial grade active ingredients, peptide raw materials, and finished formulations available for global export.
Tirofiban Hydrochloride (CAS Registry Number: 144494-65-5 for monohydrate, 150915-40-5 for free base) represents a milestone achievement in synthetic cardiovascular medicinal chemistry. As a non-peptide, highly specific antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, Tirofiban Hydrochloride exerts a powerful antithrombotic effect by reversibly inhibiting platelet aggregation—the final common pathway of intra-arterial thrombus formation.
For generic drug manufacturers, hospital procurement network heads, and clinical-grade pharmaceutical distributors, sourcing commercial bulk quantities of high-purity Tirofiban Hydrochloride API requires strict adherence to cGMP standards, rigorous impurity profiling, and a robust global logistics framework capable of maintaining cold-chain integrity. Gentolex Group stands at the forefront of providing fully validated, regulatory-compliant Tirofiban Hydrochloride API and finished dosage form (FDF) solutions.
The global demand for acute cardiovascular intervention therapies has seen exponential growth over the past decade, driven by rising incidences of coronary artery disease (CAD) and expanding healthcare infrastructure across emerging economies. Recent epidemiological shifts and clinical trial protocols have established clear trends shaping the procurement of Tirofiban Hydrochloride API:
Clinical practice guidelines from the ACC/AHA and ESC increasingly endorse high-dose bolus (HDB) administration of Tirofiban prior to PCI. HDB strategies achieve rapid (>90%) receptor occupancy, reducing ischemic events without significantly elevating bleeding risks. This clinical adoption directly drives higher volume demand for concentrated bulk solutions and stable API supplies.
With original brand patents expired worldwide, generic pharmaceutical manufacturers are expanding their market share. The competitive edge in generic manufacturing now relies on process yield optimization, green chemistry reduction of heavy metal catalysts, and maintaining enantiomeric purity (L-enantiomer > 99.8%) at commercial batch scales.
Beyond traditional cardiology, clinical investigations into intravenous Tirofiban for acute ischemic stroke (AIS) management post-thrombolysis or endovascular thrombectomy (EVT) have shown strong efficacy. This dual-specialty application expands the commercial addressable market for bulk Tirofiban suppliers.
The manufacturing process of Tirofiban Hydrochloride requires multi-step stereospecific organic synthesis to ensure absolute chiral integrity of the L-tyrosine backbone. Gentolex’s standardized production route involves the strategic coupling of modified piperidine derivatives with sulfonated L-tyrosine intermediates:
| Synthetic Stage | Chemical Transformation | Critical Quality Attributes (CQAs) | Process Controls |
|---|---|---|---|
| Stage 1: Etherification | Alkylation of protected L-Tyrosine with 4-(4-piperidinyl)butyl halide derivative | Regioselectivity & Ether bond purity | HPLC purity check ≥ 98.0%, control of unreacted Tyrosine derivative |
| Stage 2: Sulfonylation | Reaction of intermediate with n-Butanesulfonyl chloride in basic media | Sulfonamide conversion efficiency | Temperature monitoring (< 5°C), residual sulfonyl chloride monitoring |
| Stage 3: Deprotection & Salt Formation | Acid hydrolysis of protective groups followed by HCl salt formation and crystallization | Chiral purity, polymorph control, heavy metal removal | Enantiomeric excess (e.e.) > 99.8%, ICP-MS elemental impurity check |
| Stage 4: Lyophilization / Finishing | Controlled crystallization into Monohydrate crystal lattice form | Water content (3.4% - 4.5%), particle size distribution | Karl Fischer Titration, Powder XRD analysis |
Process-related impurities, such as D-enantiomer content, bis-alkylated side products, and residual organic solvents (THF, DMF, Triethylamine), are strictly restricted within ICH Q3A/B guidelines. Gentolex's proprietary crystallization protocols guarantee that single maximum unidentified impurities remain below 0.05%.
Navigating complex international regulatory frameworks and establishing continuous, risk-resilient supply chains for commercial cardiovascular API procurement.
Securing marketing authorization (MA) for generic injectables requires comprehensive regulatory support from the API manufacturer. Gentolex offers full regulatory packages to streamline client dossier filings globally:
Cardiovascular APIs for emergency parenteral care demand 100% supply continuity. Gentolex implements macro supply chain solutions tailored for multi-national pharmaceutical firms:
Gentolex’s primary mission is to build robust global bridges connecting pharmaceutical innovators and generic producers with world-class active ingredients, peptide raw materials, and precision manufacturing capabilities.
With an overall modern factory construction area exceeding 250,000 square meters operating strictly under international cGMP standards, Gentolex offers scalable, high-yield, and cost-effective solutions for clients in over 10 countries. We have established localized direct support hubs in strategic regions including Mexico and South Africa.
Browse our extended product portfolio supporting complex chemical syntheses, peptide modifications, and specialty formulations.
Trusted by premier pharmaceutical enterprises, contract research organizations (CROs), and health authorities across North America, Europe, Asia, and Africa.
Stay informed with technical whitepapers, peptide synthesis advances, and therapeutic innovations written by our R&D team.
Selank Acetate is a synthetic heptapeptide derivative of human tuftsin (TKPRPGP). Explore its chemical synthesis protocols, neuroprotective profile, and industrial lyophilization standards...
Read Full Paper
Comprehensive insight into Thymosin Beta-4 commercial manufacturing, analytical characterization, actin-sequestering mechanisms, and clinical-grade compliance...
Read Full Paper
Analysis of synthetic pentadecapeptide BPC-157. Technical evaluation of solid-phase peptide synthesis (SPPS), sequence validation, and mass spectrometry profiling...
Read Full Paper
Investigating ACTH-fragment analogue Semax. Quality specifications, BDNF expression enhancement studies, and bulk storage stability parameters...
Read Full Paper
SS-31 (Elamipretide) targeted mitochondrial tetrapeptide synthesis, cardiolipin binding metrics, bioenergetic optimization, and industrial scale production routes...
Read Full PaperDetailed answers to technical, regulatory, and commercial procurement inquiries regarding Tirofiban Hydrochloride and Gentolex peptide APIs.
